Salicylate ototoxicity in patients with rheumatoid arthritis: a controlled study

JAMES T HALLA AND JOE G HARDIN

From the University of South Alabama Department of Medicine, University of South Alabama College of Medicine

SUMMARY Tinnitus or subjective hearing loss, or both, were reported by 61 of 134 (45%) patients with rheumatoid arthritis (RA) taking regular salicylates and by 73 of 182 (40%) untreated healthy subjects. In the patients with RA mean salicylate levels were not higher in those with tinnitus than in those without tinnitus, but levels were significantly higher in those with subjective hearing loss than in those with no symptoms. Twenty five per cent of the patients with RA had tinnitus or subjective hearing loss with salicylate levels <1.42 mmol/l. Audiometric responses in 31 patients correlated poorly with symptoms. Tinnitus and subjective hearing loss may be too non-specific to be reliable as tools for adjusting the salicylate level into the therapeutic range.

Key words: acoustic nerve diseases, aspirin.

The major symptoms of salicylate ototoxicity are subjective hearing loss and tinnitus.1 2 In individuals with these symptoms audiograms typically show a raised threshold for all sound frequencies, usually in the range of 20-40 dB, and the hearing loss is sensorineural.1 2 Symptoms and audiometric abnormalities are reversible within 72 hours of discontinuing salicylates.3 The degree of hearing deficit is roughly proportional to the serum salicylate level, and tinnitus has been noted to occur only with serum salicylate levels of 1.42 mmol/l or greater.1 2 4 The dose of salicylate required to produce a therapeutic or toxic level varies widely from individual to individual,1 2 5 6 indicating that some type of monitoring tool is necessary to achieve a therapeutic level while avoiding toxicity. The salicylate ototoxicity symptoms of subjective hearing loss, and especially tinnitus, are widely used for this purpose—'push to tinnitus, and, then back off slightly' having become a time honoured approach to salicylate therapy.1 4 7 The major problem with this tool is its lack of sensitivity; tinnitus may fail to occur in the presence of salicylate levels in the toxic range, especially in older individuals with a pre-existing high tone hearing loss.1 4

We have also observed problems owing to the non-specificity of this tool. Patients with rheumatic disease who were not taking salicylates frequently reported subjective hearing loss or tinnitus, and, more confounding, patients who were taking salicylates often reported subjective hearing loss or tinnitus with subtherapeutic salicylate levels. Because these observations further challenge the validity of symptomatic salicylate ototoxicity as a tool for accurately adjusting the salicylate dose, the present study was undertaken in an effort to determine the specificity of subjective hearing loss and tinnitus as measures of the therapeutic or toxic serum salicylate levels.

Subjects and methods

SUBJECTS
The test subjects were 134 consecutive patients with definite or classical rheumatoid arthritis (RA) (American Rheumatism Association criteria) who reported the regular use of aspirin or a salicylate preparation for longer than a week with no change in the dosage schedule over the week before the study. Their mean age was 58.3 years (range 20-88). The control subjects were 182 healthy volunteers who reported no regular salicylate (or aspirin) use. Their mean age was 34.3 years (range 20-61).
INTERVIEW

In a structured interview all subjects were questioned about recent symptoms of subjective hearing loss and tinnitus and previous history of ear disease or known hearing loss. Tinnitus was defined as a recurrent unilateral or bilateral ringing, roaring, or buzzing sensation with each recurrence persisting for five minutes or longer. Based on their response to these questions subjects were divided into four groups: (1) those with both subjective hearing loss and tinnitus; (2) those with tinnitus alone; (3) those with subjective hearing loss alone; and (4) those with neither.

SALICYLATE LEVELS

At the time of the interview blood was obtained from all of the 134 patients with RA for a serum salicylate determination. All salicylate levels were measured in one laboratory by the ultraviolet spectrophotometric method of Keller.8

AUDIOMETRY

Representative patients with RA from each of the four groups defined above were selected for audiometry. The audiological examination, including pure tone air and bone threshold testing, speech reception threshold testing, and speech discrimination testing, was performed by a certified audiologist under controlled conditions.

STATISTICAL METHODS

Statistical significance was calculated using t tests on paired samples and \( \chi^2 \) tests on percentages for the four group comparison.

Results

The number of RA and control subjects in each of the four groups is shown in Table 1. There were no significant differences between the RA and control subjects with regard to any combination of these symptoms. Patients with RA in group 1 were significantly older than those in group 2 (\( p=0.02 \)) and group 4 (\( p<0.01 \)). Those with tinnitus (groups 1 and 2) were not significantly older than those without (groups 3 and 4); RA patients with subjective hearing loss (groups 1 and 3), however, were significantly older than those without (groups 2 and 4) (\( p<0.01 \)).

Serum salicylate levels in the 134 patients with RA are given in Table 2. The mean level tended to be lower in the asymptomatic group than in the three groups with symptoms, but there was a significant difference only between groups 3 and 4. Subjects with tinnitus (groups 1 and 2) (mean salicylate level 1.27 mmol/l) did not differ from those without (groups 3 and 4) (mean salicylate level 1.23 mmol/l); the mean salicylate level in patients with subjective hearing loss (groups 1 and 3) (1.47 mmol/l), however, was significantly higher (\( p=0.02 \)) than in those without (groups 2 and 4) (1.17 mmol/l). Most patients with tinnitus and subjective hearing loss (or tinnitus alone) had serum salicylate levels less than 1.42 mmol/l. Only in the group with subjective hearing loss alone did the majority have levels greater than 1.42 mmol/l. A total of 33 patients or 25% of the patients with RA had symptoms suggestive of ototoxicity with salicylate levels less than 1.42 mmol/l.

Of the 134 patients with RA, 32 had an earlier history of ear disease or known hearing loss before salicylate use. These patients were older than those without prior ear disease (mean age 66 v 56 years) and more often had tinnitus (62% v 25%). Those patients with tinnitus and prior ear disease had a significantly lower salicylate level than those subjects with tinnitus and no earlier ear disease (1.17 mmol/l v 1.38 mmol/l, \( p<0.05 \)).

Table 3 details the audiometric responses of 31 patients with RA and relates these responses to serum salicylate levels. A sensorineural hearing loss

**Table 1** Comparison of the prevalence of symptoms in rheumatoid arthritis and control groups

<table>
<thead>
<tr>
<th></th>
<th>RA (n=134)</th>
<th>Control (n=182)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No (%)</td>
<td>No (%)</td>
</tr>
<tr>
<td>Tinnitus (T)</td>
<td>46 (34)*</td>
<td>46 (25)*</td>
</tr>
<tr>
<td>Subjective hearing loss (SII)</td>
<td>42 (31)</td>
<td>51 (28)</td>
</tr>
</tbody>
</table>

**Subgroups**

(1) T and SII | 27 (20)* | 66 | 24 (13)* |
(2) T alone   | 19 (14)  | 56 | 22 (12)  |
(3) SII alone | 15 (11)  | 68 | 27 (15)  |
(4) Neither    | 73 (55)  | 55 | 109 (60) |

*NS.

**Table 2** Mean serum salicylate levels and the number of patients having a salicylate level greater than 1.42 mmol/l in the 134 patients with rheumatoid arthritis

<table>
<thead>
<tr>
<th>Group</th>
<th>Mean salicylate level (mmol/l)</th>
<th>Number (%) with salicylate level:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&gt;1.42 mmol/l</td>
</tr>
<tr>
<td>(1) T and SII</td>
<td>1.34</td>
<td>9 (33)</td>
</tr>
<tr>
<td>(2) T alone</td>
<td>1.21</td>
<td>8 (42)</td>
</tr>
<tr>
<td>(3) SII alone</td>
<td>1.70*</td>
<td>11 (73)</td>
</tr>
<tr>
<td>(4) Neither</td>
<td>1.14*</td>
<td>30 (41)</td>
</tr>
</tbody>
</table>

\( T = \) tinnitus; SII = subjective hearing loss.\n
*p<0.01.
Tinnitus; SHL=subjective hearing loss.

**Table 3** Audiometric responses in relation to serum salicylate levels above and below 1-42 mmol/l in patients with RA taking salicylates

<table>
<thead>
<tr>
<th>(1)</th>
<th>(2)</th>
<th>(3)</th>
<th>(4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>T and SHL</td>
<td>T alone</td>
<td>SHL alone</td>
<td>Neither</td>
</tr>
<tr>
<td>Number of patients</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Salicylate level</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;1-42 mmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1-42 mmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensorineural hearing loss*</td>
<td>mild</td>
<td>moderate</td>
<td>severe</td>
</tr>
<tr>
<td>&gt;1-42 mmol/l</td>
<td>6</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>&lt;1-42 mmol/l</td>
<td>4</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

T=tinnitus; SHL=subjective hearing loss.

*Mild=pure tone thresholds indicating 25-40 dB hearing loss; moderate=pure tone thresholds indicating 40-60 dB hearing loss; severe=pure tone thresholds indicating 60-80 dB hearing loss.

was recorded in 24 of the 31 patients. About half of the patients with no symptoms or tinnitus alone had normal responses, whereas none with tinnitus and subjective hearing loss or subjective hearing loss alone did. Seventeen of the 24 subjects (71%) with an abnormal audiogram had salicylate levels above 1-42 mmol/l, although only 11 of the entire group of 31 patients had levels less than 1-42 mmol/l.

**Discussion**

It had been estimated that 36 million Americans have tinnitus, and subjective hearing loss may be even more common. Our survey of a relatively young and healthy population indicated that 40% had one or both of these complaints. The slightly higher prevalence of tinnitus and subjective hearing loss in our RA population could have been due to their older age, which renders the difference between these two groups even less significant. Severity of symptoms was not addressed in this study, however, and it is possible that the patients with RA had more persisting tinnitus and more severe subjective hearing loss. In one study subnormal hearing was confirmed in one third of a small group of patients with RA not taking salicylates, suggesting that RA itself may cause hearing loss. These observations do suggest that simply inquiring about tinnitus and subjective hearing loss during the course of salicylate therapy in patients with RA may mislead the physician into adjusting the dosage into the subtherapeutic range.

Our patients were taking a variety of salicylate preparations in different dosages ranging from less than 1 g to more than 4 g/day, but all claimed to be taking them on a regular basis, and all had been taking the drug for longer than a week. In this study salicylate level measurements were not timed to reflect trough and peak levels consistently, but, if our information from the patient is correct, a steady state should have been reached, minimising differences between the two levels. Most symptomatic patients had a history of fluctuating tinnitus (as did most symptomatic controls), and this study made no effort to temporally correlate waxing symptoms with immediate blood levels of salicylate as did that of Mongan and colleagues. This study was not intended to record that one can predictably induce tinnitus or subjective hearing loss with certain dosages or blood levels of salicylate. We did show, however, that a history of these symptoms over the preceding few days correlates poorly with a single random serum salicylate measurement. In fact, most patients with these symptoms had levels less than the 1-42 mmol/l cut off point suggested by Mongan and colleagues. This was probably due to the prevalence of tinnitus and subjective hearing loss in the general population and the fact that few of our patients had levels above 2-17 mmol/l. The results of this study, however, suggest that some individuals may develop salicylate ototoxicity with subtherapeutic serum salicylate levels, a possibility that requires further study.

Unfortunately, only 11 of the 31 subjects selected for audiometric studies had salicylate levels less than 1-42 mmol/l (compared with 76 of the entire group of 134), and this fact may bias those observations. Four of 11 subjects with a salicylate level less than 1-42 mmol/l had a normal audiometric response, whereas 17 of 20 patients with a level greater than 1-42 mmol/l had an abnormal response. On the other hand, only three of the eight patients with no tinnitus or subjective hearing loss had a normal audiometric response, indicating a generally poor correlation between symptoms and audiometry.

The results of this study tend to confirm the previous suggestion of Champion and colleagues that symptoms of ototoxicity are insufficiently specific to be a reliable indicator of a therapeutic serum salicylate level. Tinnitus and subjective hearing loss are little more common in patients with RA taking salicylates than in a normal untreated population. Symptoms suggestive of ototoxicity usually occur in patients with random subtherapeutic salicylate levels, and these levels, even when above 1-42 mmol/l, correlate imperfectly with symptoms or audiometric responses. Older age and pre-existing ear disease render symptoms of ototoxicity especially unreliable when attempting to use them to adjust a salicylate level into the therapeutic range.
Salicylate ototoxicity in patients with rheumatoid arthritis

References

9 Yanick P. What is the hearing and tinnitus help assn.? Hear Instruments 1985; 36: 53.
Salicylate ototoxicity in patients with rheumatoid arthritis: a controlled study.

J T Halla and J G Hardin

doi: 10.1136/ard.47.2.134

Updated information and services can be found at:

http://ard.bmj.com/content/47/2/134

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/